[{"uuid": "43b66ede-c1ed-344f-a64a-02fd4298522b", "title": "Pfizer to Pay $60 Million in Kickback, False Claims Settlement", "publisher": "The Wall Street Journal", "link": "https://finance.yahoo.com/m/43b66ede-c1ed-344f-a64a-02fd4298522b/pfizer-to-pay-%2460-million-in.html", "providerPublishTime": 1737758880, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Fwf5HL4GsEGPbDfR3MJBPg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8", "width": 1200, "height": 630, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zIJaagDuCJitt1Cvcwyc7A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN", "PFE"]}, {"uuid": "6bdf0bef-4c57-3d3f-9a88-72433417f815", "title": "Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/merus-n-v-mrus-biotech-160831251.html", "providerPublishTime": 1737130111, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RW39hbU_Gk0ejdIi3apeRQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b0ff733069ce703c558386138d963e9f", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/tr4FlIInU9Kawabg4BIPAw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b0ff733069ce703c558386138d963e9f", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MRUS"]}, {"uuid": "bcfa8b1a-ec29-34fa-aeb5-03bbf9429f4d", "title": "Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/merus-biohaven-partner-develop-bispecific-094910348.html", "providerPublishTime": 1736761750, "type": "STORY", "relatedTickers": ["MRUS"]}, {"uuid": "297ecdce-ec9d-3a74-9f4d-29cdc441183f", "title": "Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/biohaven-highlights-portfolio-progress-innovation-161500441.html", "providerPublishTime": 1736784900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/nLvTZ_W4JqbXNXJO_9W34A--~B/aD0xODQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/cc7c2f44faad638108cc3a2024087ba7", "width": 400, "height": 184, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EJ5vOeD.VMhrtTTAbGXubg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/cc7c2f44faad638108cc3a2024087ba7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN"]}, {"uuid": "9767b198-bf2c-315b-89ca-29b14c70b5fc", "title": "Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/merus-biohaven-announce-collaboration-co-010400714.html", "providerPublishTime": 1736730240, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/85tFTiTtqrHSPucrBuUDdQ--~B/aD0xNTQyO3c9NTUxNzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6656d550a3890b225b38130b59dc1b74", "width": 5517, "height": 1542, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ph8qSJl726WmZmx5XKeAjg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6656d550a3890b225b38130b59dc1b74", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MRUS", "BHVN"]}, {"uuid": "7313e425-a764-3324-b9b8-6c3e82d0a387", "title": "Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/biohaven-present-43rd-annual-j-225400301.html", "providerPublishTime": 1736290440, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Duiufk0ancRB3jZX3mKC2g--~B/aD0xMTc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/97c920f549c08730efa2caa3d86a161a", "width": 400, "height": 117, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/oS7hPpt8frHh6DekC0ICDQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/97c920f549c08730efa2caa3d86a161a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN"]}, {"uuid": "0ae22afb-c5c3-3492-9ce5-bcffbd24fb38", "title": "Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/insider-buying-biohaven-independent-director-100429662.html", "providerPublishTime": 1735898669, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eZ0FiSKCVDYnTK6X1bRieQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN"]}, {"uuid": "a64168e5-e096-319a-8983-8b62b7416f13", "title": "Company News for Jan 2, 2025", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/company-news-jan-2-2025-083900222.html", "providerPublishTime": 1735807140, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/IW5EhxEFuSd4V4nUFOhT_A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/AxvgHTECT_FnPZu0GsWG_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN", "PFE", "X"]}, {"uuid": "1010534c-cae7-3ffa-99d1-b2b6b5e3ea21", "title": "Biohaven Insider Bought Shares Worth $1,042,393, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/biohaven-insider-bought-shares-worth-120822959.html", "providerPublishTime": 1735646902, "type": "STORY"}, {"uuid": "f4c6d810-0d3f-316c-99c2-860d22b775df", "title": "Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/biohaven-says-bhv-1300-achieves-133207981.html", "providerPublishTime": 1734355927, "type": "STORY"}, {"uuid": "f90a724b-fe13-335a-bd83-19ec6c73c121", "title": "Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/biohaven-ltd-bhvn-best-weight-110653262.html", "providerPublishTime": 1734433613, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/gUz9HDzH4plaJj0_SE7bmQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2d1436f3ebd76fdb45ce5da9242e82b8", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Xepn6pM2jfSumQQ.TXyS0Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2d1436f3ebd76fdb45ce5da9242e82b8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN"]}, {"uuid": "fe2de022-45e4-30f2-8d39-dea8e90970cf", "title": "Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/biohaven-advances-immunotherapy-significant-igg-192331593.html", "providerPublishTime": 1734463411, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/jixIN0XKvSsaFCN7J9kiYA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/88d1bb1cedb1cd4380fbdf7d29775094", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/91r3ERlcZr5hRqavQWaqLQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/88d1bb1cedb1cd4380fbdf7d29775094", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BHVN"]}]